- Report
- April 2018
- 112 Pages
Global
From €4087EUR$4,250USD£3,506GBP
- Report
- April 2023
- 394 Pages
Global
From €7212EUR$7,500USD£6,187GBP
- Report
- August 2022
- 116 Pages
Global
From €4327EUR$4,500USD£3,712GBP
- Report
- March 2018
- 90 Pages
North America
From €3702EUR$3,850USD£3,176GBP
- Report
- January 2022
- 119 Pages
Global
From €4279EUR$4,450USD£3,671GBP
- Report
- October 2021
- 131 Pages
Global
From €10572EUR$10,995USD£9,069GBP
- Report
- September 2023
- 231 Pages
China
From €3846EUR$4,000USD£3,299GBP
- Report
- January 2021
- 142 Pages
China, Global
From €3000EUR$3,342USD£2,664GBP
- Report
- September 2023
- 103 Pages
China
From €1731EUR$1,800USD£1,485GBP
- Report
- September 2023
- 74 Pages
China
From €1731EUR$1,800USD£1,485GBP
- Report
- May 2023
- 147 Pages
Global
From €5768EUR$5,999USD£4,948GBP
Cisplatin is a chemotherapy drug used to treat a variety of cancers, including lung cancer. It works by damaging the DNA of cancer cells, preventing them from growing and dividing. Cisplatin is often used in combination with other drugs to increase its effectiveness. It is administered intravenously and can cause side effects such as nausea, vomiting, and hair loss.
The market for cisplatin in the treatment of lung cancer is highly competitive, with many companies offering their own versions of the drug. Companies such as Bristol-Myers Squibb, Pfizer, and Merck & Co. are all major players in the market. Other companies, such as Teva Pharmaceuticals and Mylan, also offer generic versions of the drug.
In the market for cisplatin, companies such as Bristol-Myers Squibb, Pfizer, Merck & Co., Teva Pharmaceuticals, and Mylan are all major players. Show Less Read more
